🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Philip C. Mack

ORCID: 0000-0003-4750-3812
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile
2.3Author DataRank

Indexed papers

4in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002973
Top 11%
1.9DataRank
Top 11%47 citations

Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

Papers

Driven by 23 papers — median percentile 51. Top paper: “Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer”.

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer

JAMA Oncology(2021)10.1001/jamaoncol.2021.2209
N/A
3.1DataRank · unranked
105 citations

Mary W. Redman, Lyudmila Bazhenova, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small-Cell Lung Cancer

Clinical Lung Cancer(2017)10.1016/j.cllc.2016.11.006
N/A
2.4DataRank · unranked
39 citations

William S. Holland, Danielle Chinn, Rebekah A. Burich, Primo N. Lara, David R. Gandara +3 more

A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.09.013
N/A
2.3DataRank · unranked
79 citations

Mary W. Redman, Susanne M. Arnold, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +12 more

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002973
Top 11%
1.9DataRank
Top 11%47 citations

Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2021.06.017
N/A
0.975DataRank · unranked
662 citations

Philip C. Mack, Giorgio V. Scagliotti, Charu Aggarwal, Maria E. Arcila, Fabrice Barlési +23 more

Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3947
N/A
0.862DataRank · unranked
21 citations

Jieling Miao, Jonathan W. Riess, James Moon, Philip C. Mack, Gregory J. Gerstner +10 more

Multi-cancer early detection (MCED) tests: prioritizing equity from bench to bedside

Health Affairs Scholar(2024)10.1093/haschl/qxae039
N/A
0.850DataRank · unranked
16 citations

Jamilia Sly, Christian Rolfo, Philip C. Mack, Augusto Villanueva, Melissa Mazor +5 more

Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.05.001
N/A
0.789DataRank · unranked
18 citations

Karen L. Reckamp, Paul Frankel, Jeff Longmate, Karen A. Kelly, David R. Gandara +7 more

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol

The Lancet Oncology(2020)10.1016/s1470-2045(20)30475-7
N/A
0.725DataRank · unranked
125 citations

Vassiliki A. Papadimitrakopoulou, Katherine Minichiello, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +21 more

Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer

Journal of Experimental & Clinical Cancer Research(2022)10.1186/s13046-022-02379-1
N/A
0.710DataRank · unranked
113 citations

Alessandro Russo, Óscar Arrieta, Murat Ak, Feliciano Barrón, Muthukumar Gunasekaran +20 more

EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.10.002
N/A
0.659DataRank · unranked
13 citations

Mary W. Redman, James Moon, Francesco Agustoni, Roy S. Herbst, Thomas J. Semrad +6 more

Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR -Mutant NSCLC (SWOG S1403)

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0741
N/A
0.606DataRank · unranked
56 citations

Jieling Miao, Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst +7 more

Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2021.11.001
N/A
0.601DataRank · unranked
54 citations

Noy Meshulami, Alessandro Russo, Florian Krammer, Adolfo Garcı́a-Sastre, Philip C. Mack +14 more

Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9532
N/A
0.552DataRank · unranked
9 citations

Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst, Mary Ann Melnick +6 more

Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair–Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.01.001
N/A
0.524DataRank · unranked
32 citations

Mary W. Redman, Lauren A. Byers, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +12 more

Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer

Cancer Cell(2022)10.1016/j.ccell.2022.04.012
N/A
0.442DataRank · unranked
18 citations

Jorge Gómez, Ananda M. Rodilla, Juan Manuel Carreño, Chih–Yuan Hsu, Christian Rolfo +43 more

The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.06.025
Top 49%
0.366DataRank
Top 49%9 citations

Fred R Hirsch, Raymond U. Osarogiagbon, Katherine K. Nishimura, Ming-Sound Tsao, William D. Travis +17 more

Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)

Journal of Thoracic Oncology(2024)10.1016/j.jtho.2024.07.024
N/A
0.326DataRank · unranked
5 citations

Xing Hua, Michael C. Wu, Khaled Tolba, Saiama N. Waqar, Konstantin H. Dragnev +10 more

State of Lung Cancer in Egypt: Moving Towards Improved Guidelines for Prevention, Screening, Treatment, and Clinical Care Programs

JTO Clinical and Research Reports(2024)10.1016/j.jtocrr.2024.100776
N/A
0.292DataRank · unranked
6 citations

Ahmed Magdy Rabea, Philip C. Mack, Janakiraman Subramanian, Ehab Khalil, Mai Sherif +27 more

Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9576
N/A
0.165DataRank · unranked
2 citations

Vassiliki A. Papadimitrakopoulou, Katherine Minichiello, David R. Gandara, Fred R. Hirsch, Philip C. Mack +14 more

Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer

Vaccines(2024)10.3390/vaccines12070713
N/A
0.104DataRank · unranked
1 citations

Chih–Yuan Hsu, Ananda M. Rodilla, Jorge Gómez, Jazz Cagan, Yuanhui Huang +19 more

SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9623
Top 100%
0DataRank
Top 100%0 citations

Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9035
N/A
0DataRank · unranked
0 citations

Mary W. Redman, David Kozono, Sam Callis, Hanna Tukachinsky, Khaled Tolba +14 more